A team of internationally recognized UB scientists with complementary expertise in the brain hormone melatonin, lung disease and infectious disease are testing melatonin as a treatment for patients with mild and moderate COVID-19.
UB’s Institutional Review Board has granted approval to the researchers to use melatonin to treat COVID-19 patients under an Investigational New Drug Approval provisionally granted by the Food and the Drug Administration.
UB’s randomized, double-blind, placebo-controlled clinical trial on melatonin is one of the few being conducted around the world, and the only one in New York State. This pilot trial will enroll 30 patients, of which 20 will be treated with melatonin and 10 will receive placebo.
The pilot study will inform the researchers whether the dose of melatonin that